| 前收市價 | 4,053.00 |
| 開市 | 4,062.00 |
| 買盤 | 4,072.00 x 0 |
| 賣出價 | 4,073.00 x 0 |
| 今日波幅 | 4,050.00 - 4,074.00 |
| 52 週波幅 | 3,900.00 - 4,873.00 |
| 成交量 | |
| 平均成交量 | 4,345,200 |
| 市值 | 6.392T |
| Beta 值 (5 年，每月) | 0.54 |
| 市盈率 (最近 12 個月) | 36.29 |
| 每股盈利 (最近 12 個月) | 112.27 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 188.00 (4.64%) |
| 除息日 | 2024年3月28日 |
| 1 年預測目標價 | 4,826.50 |
ZacksDown -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksDown -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksAll You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
